文献速递复苏、休克与脓毒症中毒与环境急症

加利福尼亚州院外心脏骤停中的纳洛酮与患者结局

Naloxone and Patient Outcomes in Out-of-Hospital Cardiac Arrests in California.
PubMed 文献 · JAMA Netw Open · 2024-08-01
一句话结论回顾性队列显示,EMS给予纳洛酮与院外心脏骤停患者ROSC及出院存活率升高相关,需进一步评估。

该回顾性队列纳入2015至2023年北加州3个县5个EMS机构治疗的8195例非创伤性院外心脏骤停成人患者,其中715例(8.7%)被治疗人员认为是药物相关OHCA,1165例(14.2%)接受了纳洛酮。采用倾向评分模型分析,纳洛酮与ROSC升高相关(最近邻匹配ARD 15.2%,95%CI 9.9%-20.6%;逆概率加权回归ARD 11.8%,95%CI 7.3%-16.4%),也与出院存活率升高相关(ARD 6.2%,95%CI 2.3%-10.0%;ARD 3.9%,95%CI 1.1%-6.7%)。ROSC的NNT为9,出院存活的NNT为26。在药物相关和非药物相关OHCA亚组中,纳洛酮均与出院存活改善相关(OR分别为2.48和1.35)。作者认为这些发现支持进一步评估纳洛酮作为心脏骤停救治的一部分。

要点

  • 在8195例EMS治疗的非创伤性OHCA成人中,14.2%(1165例)接受了纳洛酮,8.7%(715例)被治疗人员认为是药物相关OHCA。
  • 纳洛酮与ROSC升高相关:最近邻倾向匹配ARD 15.2%(95%CI 9.9%-20.6%),逆概率加权回归ARD 11.8%(95%CI 7.3%-16.4%)。
  • 纳洛酮与出院存活率升高相关:最近邻倾向匹配ARD 6.2%(95%CI 2.3%-10.0%),逆概率加权回归ARD 3.9%(95%CI 1.1%-6.7%)。
  • 纳洛酮的NNT:ROSC为9,出院存活为26。
  • 药物相关OHCA亚组出院存活OR 2.48(95%CI 1.34-4.58),非药物相关OHCA亚组OR 1.35(95%CI 1.04-1.77)。

适用人群与场景

  • 2015至2023年北加州3个县、5个EMS机构治疗的18岁及以上非创伤性院外心脏骤停患者。

研究设计与关键结果

  • 研究类型:回顾性队列研究;样本量8195例;2015至2023年北加州3个县5个EMS机构;中位年龄65岁(IQR 51-78),男性5540例(67.6%);亚裔、夏威夷原住民或太平洋岛民1304例(15.9%),黑人1119例(13.7%),白人2538例(31.0%)。
  • 暴露:EMS给予纳洛酮(1165例,14.2%);715例(8.7%)被治疗人员认为是药物相关OHCA。
  • 主要终点出院存活:最近邻倾向匹配ARD 6.2%(95%CI 2.3%-10.0%);逆概率加权回归ARD 3.9%(95%CI 1.1%-6.7%)。
  • 次要终点持续ROSC:最近邻倾向匹配ARD 15.2%(95%CI 9.9%-20.6%);逆概率加权回归ARD 11.8%(95%CI 7.3%-16.4%)。
  • NNT:ROSC为9,出院存活为26。
  • 效应修饰回归模型:药物相关OHCA组出院存活OR 2.48(95%CI 1.34-4.58);非药物相关OHCA组OR 1.35(95%CI 1.04-1.77)。

证据类型、等级与局限

  • 证据类型:回顾性队列研究;数据采用倾向评分模型分析(2024年2月至4月分析)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,这些发现支持进一步评估纳洛酮作为心脏骤停救治的一部分。

指南或共识出处

  • 美国心脏协会(AHA)方案建议:EMS临床医生在阿片相关院外心脏骤停中考虑使用纳洛酮。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: The incidence of opioid-associated out-of-hospital cardiac arrest (OA-OHCA) has grown from less than 1% of OHCA in 2000 to between 7% and 14% of OHCA in recent years; American Heart Association (AHA) protocols suggest that emergency medical service (EMS) clinicians consider naloxone in OA-OHCA. However, it is unknown whether naloxone improves survival in these patients or in patients with undifferentiated OHCA.

OBJECTIVE: To evaluate the association of naloxone with clinical outcomes in patients with undifferentiated OHCA.

DESIGN, SETTING, AND PARTICIPANTS: Retrospective cohort study of EMS-treated patients aged 18 or older who received EMS treatment for nontraumatic OHCA in 3 Northern California counties between 2015 and 2023. Data were analyzed using propensity score-based models from February to April 2024.

EXPOSURE: EMS administration of naloxone.

MAIN OUTCOMES AND MEASURES: The primary outcome was survival to hospital discharge; the secondary outcome was sustained return of spontaneous circulation (ROSC). Covariates included patient and cardiac arrest characteristics (eg, age, sex, nonshockable rhythm, any comorbidity, unwitnessed arrest, and EMS agency) and EMS clinician determination of OHCA cause as presumed drug-related.

RESULTS: Among 8195 patients (median [IQR] age, 65 [51-78] years; 5540 male [67.6%]; 1304 Asian, Native Hawaiian, or Pacific Islander [15.9%]; 1119 Black [13.7%]; 2538 White [31.0%]) with OHCA treated by 5 EMS agencies from 2015 to 2023, 715 (8.7%) were believed by treating clinicians to have drug-related OHCA. Naloxone was administered to 1165 patients (14.2%) and was associated with increased ROSC using both nearest neighbor propensity matching (absolute risk difference [ARD], 15.2%; 95% CI, 9.9%-20.6%) and inverse propensity-weighted regression adjustment (ARD, 11.8%; 95% CI, 7.3%-16.4%). Naloxone was also associated with increased survival to hospital discharge using both nearest neighbor propensity matching (ARD, 6.2%; 95% CI, 2.3%-10.0%) and inverse propensity-weighted regression adjustment (ARD, 3.9%; 95% CI, 1.1%-6.7%). The number needed to treat with naloxone was 9 for ROSC and 26 for survival to hospital discharge. In a regression model that assessed effect modification between naloxone and presumed drug-related OHCA, naloxone was associated with improved survival to hospital discharge in both the presumed drug-related OHCA (odds ratio [OR], 2.48; 95% CI, 1.34-4.58) and non-drug-related OHCA groups (OR, 1.35; 95% CI, 1.04-1.77).

CONCLUSIONS AND RELEVANCE: In this retrospective cohort study, naloxone administration as part of EMS management of OHCA was associated with increased rates of ROSC and increased survival to hospital discharge when evaluated using propensity score-based models. Given the lack of clinical practice data on the efficacy of naloxone in OA-OHCA and OHCA in general, these findings support further evaluation of naloxone as part of cardiac arrest care.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Dillon DG, Montoy JCC, Nishijima DK, et al. Naloxone and Patient Outcomes in Out-of-Hospital Cardiac Arrests in California. JAMA Netw Open. 2024. PMID: 39163042. doi:10.1001/jamanetworkopen.2024.29154

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。